PHARMA UNITED: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMA UNITED
Largest movements
- Receivables within one year -€43,190
down €43,190 (-36.4%), from €118,495 to €75,305
of which Trade receivables: -€109,646
- Cash -€5,037
down €5,037 (-65.7%), from €7,668 to €2,631
mainly Net result for the year (-€63,433) and Tax, wage and social debts (-€356)
- Profit (loss) carried forward -€63,433
down €63,433 (-11.2%), from -€566,838 to -€630,271
- Other debts +€10,000
new in 2025: €10,000
- Trade debts +€5,478
up €5,478 (+2391.9%), from €229 to €5,707
- Gross operating margin -€88,408
down €88,408, from €70,847 to -€17,561
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €126,247 | €77,937 | -€48,311 | -38.3% |
| Current assets | 29/58 | €126,247 | €77,937 | -€48,311 | -38.3% |
| Amounts receivable within one year | 40/41 | €118,495 | €75,305 | -€43,190 | -36.4% |
| Trade receivables | 40 | €109,646 | - | -€109,646 | |
| Other amounts receivable | 41 | €8,849 | €75,305 | +€66,456 | +751.0% |
| Cash at bank and in hand | 54/58 | €7,668 | €2,631 | -€5,037 | -65.7% |
| Deferred charges and accrued income | 490/1 | €84 | €1 | -€83 | -98.7% |
| Total equity and liabilities | 10/49 | €126,247 | €77,937 | -€48,311 | -38.3% |
| Equity | 10/15 | €125,662 | €62,229 | -€63,433 | -50.5% |
| Contributions | 10/11 | €692,500 | €692,500 | = | 0.0% |
| Capital | 10 | €692,500 | €692,500 | = | 0.0% |
| Issued capital | 100 | €692,500 | €692,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€566,838 | -€630,271 | -€63,433 | -11.2% |
| Amounts payable | 17/49 | €585 | €15,707 | +€15,122 | +2584.4% |
| Amounts payable within one year | 42/48 | €585 | €15,707 | +€15,122 | +2584.4% |
| Trade debts | 44 | €229 | €5,707 | +€5,478 | +2391.9% |
| Suppliers | 440/4 | €229 | €5,707 | +€5,478 | +2391.9% |
| Taxes, remuneration and social security | 45 | €356 | - | -€356 | |
| Taxes | 450/3 | €356 | - | -€356 | |
| Other amounts payable | 47/48 | - | €10,000 | +€10,000 | |
| Other operating charges | 640/8 | €118 | €315 | +€197 | +166.8% |
| Non-recurring operating charges | 66A | - | €45,485 | +€45,485 | |
| Gross operating margin | 9900 | €70,847 | -€17,561 | -€88,408 | |
| Operating profit (loss) | 9901 | €70,729 | -€63,361 | -€134,090 | |
| Financial income | 75/76B | - | €4 | +€4 | |
| Recurring financial income | 75 | - | €4 | +€4 | |
| Financial charges | 65/66B | €7 | €75 | +€69 | +1046.2% |
| Recurring financial charges | 65 | €7 | €75 | +€69 | +1046.2% |
| Profit (loss) for the period before taxes | 9903 | €70,722 | -€63,433 | -€134,155 | |
| Profit (loss) for the period | 9904 | €70,722 | -€63,433 | -€134,155 | |
| Profit (loss) for the period to be appropriated | 9905 | €70,722 | -€63,433 | -€134,155 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 12 October 2026 via checked.be.